Recurrent Nasopharyngeal Carcinoma Clinical Trial
Official title:
Adjuvant Therapy Versus Endoscopic Surgery Alone in Early-stage Recurrent Nasopharyngeal Carcinoma: A Multicenter Randomized Controlled Trial
Adjuvant Therapy Versus Endoscopic Surgery Alone in Early-stage Recurrent Nasopharyngeal Carcinoma: A Multicenter Randomized Controlled Trial
This study is an open-label, multicentered, evaluator-blinded , randomized clinical trial. Patients with early-stage recurrent nasopharyngeal carcinoma were randomized into the control group and the experimental group. Patients in the control group would go through observation and follow-up after recurrent endoscopic surgery, while patients in the experimental group would be treated with adjuvant therapy such as chemotherapy and immunotherapy. A total of 176 subjects are required, with 88 patients in the control group and 88 patients in the experimental group. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT06010095 -
Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer
|
Phase 2 | |
| Recruiting |
NCT03639467 -
Study of Anlotinib Combined With Gemcitabine/Cisplatin in Advanced Nasopharyngeal Carcinoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06029270 -
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
|
Phase 2 | |
| Recruiting |
NCT03666221 -
Nimotuzumab for Recurrent Nasopharyngeal Carcinoma
|
Phase 2 | |
| Recruiting |
NCT05350891 -
Transnasal Endoscopic Surgery Combined With Adjuvant Immunotherapy for Recurrent NPC
|
Phase 2 | |
| Active, not recruiting |
NCT04586088 -
Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure
|
Phase 2 | |
| Active, not recruiting |
NCT04405622 -
Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma.
|
Phase 2 | |
| Recruiting |
NCT06235203 -
Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC
|
Phase 3 | |
| Not yet recruiting |
NCT04215510 -
Early Recurrent Nasopharyngeal Cancer: the Effect of Surgery vs IMRT
|
Phase 3 | |
| Recruiting |
NCT03930498 -
Programmed Death-1 (PD-1) Antibody Combined With Chemoradiotherapy in High-risk Recurrent Nasopharyngeal Carcinoma
|
Phase 2 | |
| Recruiting |
NCT03907826 -
PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients
|
Phase 3 | |
| Recruiting |
NCT04376866 -
Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma
|
Phase 3 | |
| Not yet recruiting |
NCT05432219 -
A Transoral Retropterygoid Approach to Resect Recurrent Nasopharyngeal Carcinoma
|
N/A | |
| Recruiting |
NCT04425265 -
Plasma Radiofrequency Ablation at Low Temperature Versus Electrocautery Block Resection at High Frequency for Localized Recurrent Nasopharyngeal Carcinoma
|
N/A | |
| Not yet recruiting |
NCT03689556 -
Examine the Prognostic Role of FLT PET/CT for Patients With LR-NPC Treated by Carbon Ion Therapy
|
||
| Not yet recruiting |
NCT03210389 -
A Clinical Trial of Chemotherapy With Lobaplatin and 5-FU in Recurrent Local or Distant Advanced NPC.
|
Phase 2 | |
| Completed |
NCT01370070 -
MK-2206 in Recurrent Nasopharyngeal Carcinoma
|
Phase 2 | |
| Completed |
NCT01392235 -
Famitinib in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma (NPC)
|
Phase 2 | |
| Terminated |
NCT04458909 -
Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer
|
Phase 3 | |
| Withdrawn |
NCT04231864 -
Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer
|
Phase 2 |